Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Stock Information for Northwest Biotherapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Northwest Biotherapeutics Inc

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
Crown Equity Holdings, Inc. Files Registration Statement on Form S-1 for Proposed Public Offering of its Common Stock
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.